N/A N=25 Lens Wear Schedules and End-of-Day Comfort
Myopia
Primary: Mean End-of-Day Comfort — 48.9; 56.0; 51.4; 53.7 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=55 Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
Relapsed Follicular Lymphoma
Primary: Number of Patients With Complete Response (CR) — 1; 13 participants
Phase 2 N=678 Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate
Influenza
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms. — 2; 14; 0; 1 subjects
Phase 3 N=136 Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
Cytomegalovirus Infections
Primary: Incidence of CMV End Organ Disease — 21; 1 participants
Phase 3 N=140 Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)
Anesthesia, General
Primary: Time From Start of Administration of Investigational Medicinal Product (IMP, Sugammadex or Neostigmine) to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to…
Phase 3 N=18,201 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
Atrial Fibrillation · Atrial Flutter
Primary: Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period — 159; 173…
Phase 2 N=119 Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
Macular Degeneration
Primary: Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye — 6.219; 6.897; 5.526; 0.898 Disc Area
Phase 2 N=333 Efficacy of Naltrexone in Women's Smoking Cessation
Smoking · Smoking Cessation
Primary: Prolonged Smoking Abstinence: 4 Weeks Post Quit-Date — 43; 29; 40; 39 Participants
Phase 4 N=383 A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China
Erectile Dysfunction
Primary: Percentage of Participants Preferring Tadalafil Over Sildenafil Measured at Week 18 Using Question 1 of the "Phosphodiesterase 5 Inhibitor Treatment Preference"…
Phase 2 N=364 Anxiety Self-Management for ICU Patients Receiving Mechanical Ventilation
Anxiety
Primary: Sedative Exposure — 1; 7; 6 exposures/4-hours per day
Phase 4 N=103 An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics
Pain; Cancer
Primary: Percentage of Participants Satisfied With Pain Treatment — 82.81 percentage of participants
Phase 1 N=50 Nicotine Lozenge Bioequivalence Study
Smoking Cessation
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Time t [AUC(0-t)] — 18.84; 20.71; 34.71; 33.68 nanogram (ng).hour (hr)/millilitre (mL)
Phase 4 N=74 AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure
Glaucoma
Primary: Change in Intraocular Pressure (IOP) at the Final Visit From Prior Beta-blocker Monotherapy (Timolol 0.5% Only) — 18.22; -3.56 millimeters mercury (mmHg)
Phase 2 N=44 Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer · Limited Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: 6 Week Progression Free Survival — 43 percentage of participants
N/A N=21 Feasibility of iFS™ for Intrastromal Arcuate Keratotomy (ISAK) Procedures
Refractive Astigmatism
Primary: Change in Refractive Astigmatism — -0.97; -0.81 Diopter of cylinder change